What retatrutide results change about weight and safety questions

What the largest retatrutide results leave unanswered

Eli Lilly hoped retatrutide could reduce weight while improving sugar control in the same treatment. Phase 2 middle tests found average loss of 24.2% over 48 weeks ^[1], the largest then measured in a drug trial.

The first Phase 3 larger report also found better sugar control in adults with type 2 diabetes. Average loss reached 15.3% by 40 weeks ^[12], measured from each person's weight before treatment.

These benefits supported earlier findings, but Phase 3 still needed to answer further safety questions. No retatrutide stopping results had been published as of 2026, so lasting weight loss remained unknown.

Before judging a benefit, you need to know who joined the study and which problems occurred. The tested amounts and length of care also matter when you weigh the gains against harms.

What Phase 2 middle tests found in obesity after 48 weeks

The retatrutide groups lost more weight than placebo, a study treatment without the drug. Gut trouble and faster pulses occurred too, which also matters to your safety.

Doctors followed 338 adults without diabetes over 48 weeks, giving injections weekly into fat under skin ^[1]. Some had obesity, while others had excess weight with another weight-related illness.

The study used a height-and-weight score, with 30 or above marking obesity. Scores from 27 to 30 also qualified if the person had another weight-related illness.

The table gives loss from starting weight after 48 weeks. Milligrams measure the amount of drug in each shot.

At 12 milligrams, waists shrank, though nausea affected up to 45%. Unwanted effects caused 18% to stop at 12 milligrams; pulse rises were strongest near week 24.

A 2025 commentary described the 24.2% loss as the largest then measured in a drug trial ^[6]. A 2024 review compared losses with weight-loss surgery ^[11], without proving the drug could replace surgery for you.

What Phase 2 middle tests found in type 2 diabetes after 36 weeks

With 12 milligrams, sugar control was much better by 24 weeks than with placebo, a treatment without retatrutide. Average weight loss reached 16.94% at 36 weeks, against 3.00% with placebo ^[2], both measured from starting weight.

The trial followed 281 adults whose diabetes wasn't well controlled by their existing medicines. Doctors increased weekly shot amounts gradually over 36 weeks while checking benefits and harms.

Gut trouble affected 35%, with doctors rating the problems mild or moderate. Nobody died or had dangerously low sugar, though a limited study can't settle your safety over years.

Sugar improvement was among the largest found with diabetes medicines, and weight loss reached 16.94%. That was below the Phase 2 obesity loss of 24.2%; diabetes and different study lengths limit comparisons.

What Phase 2a, a smaller middle test, found in liver fat over 24–48 weeks

Larger amounts reduced liver fat most, while placebo produced a 0.3% rise. Scans found at least 10% liver fat in 98 people without diabetes carrying excess weight ^[5].

Weekly shots continued for 48 weeks under medical care. The list gives liver fat lost by 24 weeks, rather than how many people improved.

• 1 milligram: 42.9% less liver fat.
• 4 milligrams: 57.0% less liver fat.
• 8 milligrams: 81.4% less liver fat.
• 12 milligrams: 82.4% less liver fat.

By 24 weeks, 86% receiving 12 milligrams reached normal liver-fat levels, below 5% fat. At week 48, liver fat fell further with 12 milligrams.

A review discussed possible heart and liver benefits ^[9]. Less fat can't promise you less future illness.

What Phase 3 larger tests found in diabetes after 40 weeks

At 12 milligrams, sugar control improved more than with placebo, a treatment without retatrutide. Average weight loss was 15.3% against 2.6% with placebo ^[12], each measured from starting weight.

Doctors followed 537 adults whose diabetes stayed poorly controlled despite diet and exercise. Over 40 weeks, the trial compared 12 milligrams with placebo and checked harms alongside weight and sugar.

Gut trouble was usually mild or moderate, though unwanted effects led 8.3% to stop retatrutide. No dangerously low sugar was reported, but the limited trial cannot answer every safety question for you.

These first Phase 3 larger results supported the benefits seen in Phase 2 middle tests. Eli Lilly needs findings like these for officials to weigh benefits and harms before possible approval.

What retatrutide results cannot show about life after stopping

Retatrutide had no published findings on life after the last injection as of mid-2026. Other medicines showed substantial weight returning, so large losses during treatment don't settle what happens afterward.

A 2025 study found regain after liraglutide, semaglutide, or tirzepatide treatment stopped ^[7]. Those drugs affect hunger, but their stopping results can't directly answer what retatrutide would do to your weight.

A 2026 review described weight returning as a main limit of this drug family ^[13]. Retatrutide's glucagon action helps use calories, but hadn't proved that weight loss lasts after stopping.

Another 2026 review asked whether glucagon might make calorie burning and reduced liver fat last longer ^[15]. The authors proposed a question for future studies, without claiming a lasting benefit had already been shown.

TRIUMPH's Phase 3 larger tests include follow-up meant to examine life once treatment ends. Phase 2 middle tests established large losses during injections, without showing whether those losses last afterward.

Published follow-up could help you weigh benefits that might persist against the need for continued treatment. Until those findings appear, your question about weight staying off remains unanswered despite the large losses during studies.